QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
NASDAQ:EKSO

Ekso Bionics (EKSO) Stock Price, News & Analysis

$1.97
0.00 (0.00%)
(As of 02/28/2024 ET)
Today's Range
$1.93
$2.04
50-Day Range
$1.60
$3.10
52-Week Range
$0.62
$3.13
Volume
33,843 shs
Average Volume
192,796 shs
Market Capitalization
$29.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Ekso Bionics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
407.6% Upside
$10.00 Price Target
Short Interest
Healthy
1.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of Ekso Bionics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.96) to ($0.20) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.57 out of 5 stars

Medical Sector

520th out of 959 stocks

General Industrial Machinery, Industry

4th out of 11 stocks


EKSO stock logo

About Ekso Bionics Stock (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therap, an adjustable and lower-limb powered exoskeleton; and Ekso Indego Personal, a powered lower limb orthosis. It has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in San Rafael, California.

EKSO Stock Price History

EKSO Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc (EKSO)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Ekso Bionics Launches GaitCoach Software for EksoNR
Ekso Bionics Holdings Inc EKSO
Q3 2023 Ekso Bionics Holdings Inc Earnings Call
See More Headlines
Receive EKSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2021
Today
2/28/2024
Next Earnings (Confirmed)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
General industrial machinery,
Sub-Industry
N/A
Current Symbol
NASDAQ:EKSO
Previous Symbol
OTCMKTS:EKSOD
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+400.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,080,000.00
Pretax Margin
-89.28%

Debt

Sales & Book Value

Annual Sales
$12.91 million
Book Value
$1.94 per share

Miscellaneous

Free Float
13,734,000
Market Cap
$29.70 million
Optionable
Optionable
Beta
1.74
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Scott G. Davis (Age 54)
    CEO & Director
    Comp: $535.8k
  • Mr. Jerome Wong (Age 50)
    Corporate Controller, Corporate Secretary & CFO
    Comp: $356.81k
  • Mr. Jason C. Jones
    Chief Operating Officer
  • Ms. Rachael Anderson
    Global Director of Marketing & Strategic Growth
  • Mr. Anthony Pratt
    Vice President of Sales
  • Ms. Ann Cookson
    Human Resources Director
  • Ms. Foon Lim Chwee
    President of APAC
  • Mr. Stephan Aderhold
    Senior VP & GM of EMEA














EKSO Stock Analysis - Frequently Asked Questions

Should I buy or sell Ekso Bionics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EKSO shares.
View EKSO analyst ratings
or view top-rated stocks.

What is Ekso Bionics' stock price target for 2024?

1 equities research analysts have issued 1 year price objectives for Ekso Bionics' shares. Their EKSO share price targets range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 407.6% from the stock's current price.
View analysts price targets for EKSO
or view top-rated stocks among Wall Street analysts.

How have EKSO shares performed in 2024?

Ekso Bionics' stock was trading at $2.50 at the start of the year. Since then, EKSO shares have decreased by 21.2% and is now trading at $1.97.
View the best growth stocks for 2024 here
.

Are investors shorting Ekso Bionics?

Ekso Bionics saw a drop in short interest in the month of February. As of February 15th, there was short interest totaling 172,100 shares, a drop of 32.0% from the January 31st total of 253,000 shares. Based on an average trading volume of 176,600 shares, the short-interest ratio is currently 1.0 days.
View Ekso Bionics' Short Interest
.

When is Ekso Bionics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our EKSO earnings forecast
.

How can I listen to Ekso Bionics' earnings call?

Ekso Bionics will be holding an earnings conference call on Monday, March 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) issued its earnings results on Monday, November, 1st. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.10. The firm had revenue of $3.05 million for the quarter, compared to analysts' expectations of $2.58 million. Ekso Bionics had a negative net margin of 89.28% and a negative trailing twelve-month return on equity of 76.01%. During the same period in the previous year, the company earned ($0.52) earnings per share.

When did Ekso Bionics' stock split?

Ekso Bionics's stock reverse split on the morning of Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What guidance has Ekso Bionics issued on next quarter's earnings?

Ekso Bionics issued an update on its fourth quarter 2023 earnings guidance on Thursday, January, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.7 million-$4.9 million, compared to the consensus revenue estimate of $4.6 million.

What other stocks do shareholders of Ekso Bionics own?
Who are Ekso Bionics' major shareholders?

Ekso Bionics' stock is owned by many different institutional and retail investors. Top institutional investors include Essex Investment Management Co. LLC (1.06%), Kent Lake Capital LLC (0.95%), Strategic Wealth Investment Group LLC (0.37%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and FNY Investment Advisers LLC (0.00%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman.
View institutional ownership trends
.

How do I buy shares of Ekso Bionics?

Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EKSO) was last updated on 2/28/2024 by MarketBeat.com Staff